Janux Therapeutics, Inc.
JANXNasdaq
$16.26
↑ +2.7%Jul 17 close · end-of-day
Price
1Y↓ -39.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.0B
Enterprise Value
$62.6M
P/E
—
P/S
74.2
P/B
1.1
EV/EBITDA
—
PEG
—
FCF Yield
-7.7%
Dividend Yield
—
Revenue (TTM)
$13.7M
Net Income (TTM)
-$114.5M
Free Cash Flow (TTM)
-$78.5M
Gross Margin
—
Operating Margin
-1143.1%
Net Margin
-833.6%
ROE
-12.2%
ROIC
—
Debt / Equity
—
Net Cash
$956.4M
Return 1Y
-41.4%
Company profile
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology. The company was incorporated in 2017 and is headquartered in La Jolla, California.
- CEO
- David Campbell
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 30
- Headquarters
- California
- Website
- januxrx.com
Management & directors
- Campbell David AlanPresident and CEO
- Doyle Janeen NoelChief Corp. & Bus. Dev. Ofcr
- Dobek MariaVice President, Accounting
- Go WilliamChief Medical Officer
- Diraimondo ThomasChief Scientific Officer
- Mciver ZachariahChief Medical Officer
- Meyer Andrew HollmanChief Business Officer
- Winter Charles M.Chief Technical Officer
Roles derived from SEC Form 4 filings.
Earnings
JANX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$3.7M—
Diluted EPS-$0.39↑ +2.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $3.6M | $8.6M | $8.1M | $10.6M | $10.0M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$4.8M | -$32.9M | -$67.1M | -$73.0M | -$98.8M | -$157.7M |
| Net income | -$6.8M | -$32.7M | -$63.1M | -$58.3M | -$69.0M | -$113.6M |
| Diluted EPS | — | -$1.39 | -$1.52 | -$1.32 | -$1.28 | -$1.83 |
| Operating cash flow | -$4.4M | -$17.0M | -$42.9M | -$50.6M | -$43.8M | -$82.2M |
| Free cash flow | -$4.4M | -$18.5M | -$49.4M | -$52.4M | -$44.2M | -$83.3M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | -905.4% | -779.0% | -902.9% | -933.6% | -1576.7% |
| Net margin | — | -898.3% | -732.2% | -721.2% | -651.6% | -1136.3% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.9M | $439,000.00 | $0.00 | $0.00 | $0.00 | $10.0M | $0.00 | $3.7M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$13.8M | -$35.8M | -$29.0M | -$34.9M | -$45.1M | -$35.3M | -$42.4M | -$34.2M |
| Net income | -$6.0M | -$28.1M | -$20.2M | -$23.5M | -$33.9M | -$24.3M | -$31.9M | -$24.4M |
| Diluted EPS | -$0.11 | -$0.51 | -$0.36 | -$0.38 | -$0.55 | -$0.39 | -$0.51 | -$0.39 |
| Operating cash flow | -$10.0M | -$2.2M | -$16.7M | -$17.0M | -$23.8M | -$12.9M | -$28.5M | -$12.3M |
| Free cash flow | -$10.1M | -$2.3M | -$16.8M | -$17.4M | -$24.3M | -$12.9M | -$28.6M | -$12.6M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -155.4% | -8164.5% | — | — | — | -352.5% | — | -916.5% |
| Net margin | -67.0% | -6391.6% | — | — | — | -243.1% | — | -652.6% |
Company news
May 28, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-08 | Campbell David Alan· President and CEO | Option exercise | 7,000 | $4.21 | $29,470.00 | filing |
| 2026-06-11 | RA CAPITAL MANAGEMENT, LLC | Award | 5,500 | $0.00 | $0.00 | filing |
| 2026-06-11 | Kung Winston | Award | 5,500 | $0.00 | $0.00 | filing |
| 2026-06-11 | Hernday Natasha | Award | 5,500 | $0.00 | $0.00 | filing |
| 2026-06-11 | DOBMEIER ERIC | Award | 5,500 | $0.00 | $0.00 | filing |
| 2026-06-11 | CAPPS VICKIE L | Award | 5,500 | $0.00 | $0.00 | filing |
| 2026-06-11 | Simson Jake | Award | 5,500 | $0.00 | $0.00 | filing |
| 2026-06-11 | Barrett Ronald W | Award | 5,500 | $0.00 | $0.00 | filing |
| 2026-06-02 | Doyle Janeen Noel· Chief Corp. & Bus. Dev. Ofcr | Sale | 4,059 | $14.03 | $56,943.71 | filing |
| 2026-05-11 | Dobek Maria· Vice President, Accounting | Sale | 2,038 | $14.17 | $28,878.46 | filing |
| 2026-02-02 | Go William· Chief Medical Officer | Award | 44,000 | $0.00 | $0.00 | filing |
| 2026-01-02 | Campbell David Alan· President and CEO | Sale | 8,072 | $13.73 | $110,828.56 | filing |
| 2026-01-02 | McIver Zachariah· Chief Medical Officer | Sale | 2,714 | $13.73 | $37,263.22 | filing |
| 2026-01-02 | DiRaimondo Thomas· Chief Scientific Officer | Sale | 2,505 | $13.73 | $34,393.65 | filing |
| 2026-01-02 | Winter Charles M.· Chief Technical Officer | Sale | 2,401 | $13.73 | $32,965.73 | filing |
| 2026-01-02 | Meyer Andrew Hollman· Chief Business Officer | Sale | 1,879 | $13.73 | $25,798.67 | filing |
| 2026-01-02 | Dobek Maria· Vice President, Accounting | Sale | 1,462 | $13.73 | $20,073.26 | filing |
| 2026-01-02 | DiRaimondo Thomas· Chief Scientific Officer | Award | 31,400 | $0.00 | $0.00 | filing |
| 2026-01-02 | Campbell David Alan· President and CEO | Award | 96,600 | $0.00 | $0.00 | filing |
| 2026-01-02 | Winter Charles M.· Chief Technical Officer | Award | 28,600 | $0.00 | $0.00 | filing |
| 2026-01-02 | McIver Zachariah· Chief Medical Officer | Award | 29,000 | $0.00 | $0.00 | filing |
| 2026-01-02 | Doyle Janeen Noel· Chief Corp. & Bus. Dev. Ofcr | Award | 36,000 | $0.00 | $0.00 | filing |
| 2026-01-02 | Dobek Maria· Vice President, Accounting | Award | 18,935 | $0.00 | $0.00 | filing |
| 2025-12-01 | Meyer Andrew Hollman· Chief Business Officer | Sale | 2,700 | $32.85 | $88,707.96 | filing |
| 2025-12-01 | Meyer Andrew Hollman· Chief Business Officer | Option exercise | 3,333 | $10.59 | $35,296.47 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.